Skip to Content

Boostrix Approval History

Boostrix is a combination vaccine that provides a booster immunization against pertussis (whooping cough) in combination with tetanus and diphtheria.

Development History and FDA Approval Process for Boostrix

Jul 11, 2011Approval FDA approves Boostrix to prevent tetanus, diphtheria, and pertussis in older people
Dec 13, 2008Approval FDA Approves GlaxoSmithKline Tetanus, Diphtheria, Whooping Cough Vaccine, Boostrix, for Adults
May  3, 2005Approval Boostrix GlaxoSmithKline Biologicals - Treatment for Prevention of Diphtheria, Tetanus & Pertussis in Adolescents
Mar 15, 2005GlaxoSmithKline Receives Unanimous Favorable Recommendation by FDA Advisory Committee for Boostrix
Jul  7, 2004GlaxoSmithKline Submits Biologics License Application for FDA Approval of Boostrix

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.